Allogene Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Zachary Roberts
- Full Time Employees
- 151
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 210 East Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- Oct 11, 2018
- CIK
- 0001737287
- Website
- allogene.com
- Similar Companies
- Business
- Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. Founded in 2017 and headquartered in South San Francisco, California, the company pioneers off-the-shelf CAR T products derived from healthy donor T cells, featuring multiplex gene-engineering, gene-editing, proprietary lymphodepletion platforms, and state-of-the-art manufacturing to enable scalable access, speed, reliability, and innovation beyond autologous therapies. Its lead product candidate, cemacabtagene ansegedleucel (cema-cel), advances in the pivotal Phase 2 ALPHA3 trial as frontline consolidation therapy for large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), targeting minimal residual disease with potential MRD conversion and first data readout expected in the first half of 2026; ALLO-316 targets clear cell renal cell carcinoma (ccRCC) in the TRAVERSE trial, which completed Phase 1b enrollment in heavily pretreated patients and secured FDA alignment on a pivotal path forward, positioning it as the only allogeneic CAR T showing clinically meaningful responses in metastatic solid tumors; ALLO-329, a CD19/CD70 dual-targeting CAR with Dagger technology to potentially reduce lymphodepletion needs, enrolls in the Phase 1 RESOLUTION trial for autoimmune diseases. The company operates primarily in the United States with research and development in South San Francisco and manufacturing in Newark, California, while conducting multi-center clinical trials potentially spanning North America and Europe, supported by strategic collaborations including Pfizer, Servier, Cellectis, Regeneron, Takeda, and GSK that provide milestone payments up to billions. Recent developments include Q3 2025 financial results showing a net loss of $41.4 million on $44.9 million operating expenses, cash reserves of $277.1 million extending into late 2027, ongoing ALPHA3 patient identification and site best practices for LBCL consolidation, TRAVERSE Phase 1b completion for ALLO-316 with partnership potential, and RESOLUTION enrollment initiation for ALLO-329 in autoimmune indications, reflecting disciplined execution amid a streamlined 2025 cash burn target of approximately $170 million.
Company News
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Deutsche Bank AG Purchases Shares of 281,949 Allogene Therapeutics, Inc. $ALLO
Connor Clark & Lunn Investment Management Ltd. Invests $671,000 in Allogene Therapeutics, Inc. $ALLO
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?
Allogene Therapeutics, Inc. $ALLO Shares Acquired by Bank of America Corp DE
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics, Inc. $ALLO Shares Bought by Dimensional Fund Advisors LP
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Allogene Therapeutics Q2 Earnings Call Highlights
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $8.52 Consensus Price Target from Analysts
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences